Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Lifted by Montag A & Associates Inc.

Montag A & Associates Inc. grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 505.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 927 shares of the biopharmaceutical company's stock after acquiring an additional 774 shares during the period. Montag A & Associates Inc.'s holdings in Regeneron Pharmaceuticals were worth $814,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of REGN. FMR LLC increased its position in shares of Regeneron Pharmaceuticals by 7.3% in the third quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company's stock worth $8,098,661,000 after acquiring an additional 669,517 shares in the last quarter. International Assets Investment Management LLC increased its position in shares of Regeneron Pharmaceuticals by 76,169.5% in the fourth quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company's stock worth $519,148,000 after acquiring an additional 590,314 shares in the last quarter. abrdn plc increased its position in shares of Regeneron Pharmaceuticals by 552.8% in the fourth quarter. abrdn plc now owns 219,900 shares of the biopharmaceutical company's stock worth $193,136,000 after acquiring an additional 186,215 shares in the last quarter. Assenagon Asset Management S.A. increased its position in shares of Regeneron Pharmaceuticals by 129.3% in the fourth quarter. Assenagon Asset Management S.A. now owns 216,523 shares of the biopharmaceutical company's stock worth $190,170,000 after acquiring an additional 122,103 shares in the last quarter. Finally, National Bank of Canada FI increased its position in shares of Regeneron Pharmaceuticals by 161.8% in the fourth quarter. National Bank of Canada FI now owns 116,227 shares of the biopharmaceutical company's stock worth $105,185,000 after acquiring an additional 71,838 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN traded up $5.80 during trading hours on Friday, hitting $973.80. 348,443 shares of the stock were exchanged, compared to its average volume of 519,687. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. The company's 50 day moving average is $942.07 and its 200 day moving average is $900.30. The firm has a market capitalization of $106.88 billion, a P/E ratio of 28.77, a P/E/G ratio of 2.41 and a beta of 0.17. Regeneron Pharmaceuticals, Inc. has a one year low of $684.80 and a one year high of $998.33.

Insider Buying and Selling

In related news, EVP Andrew J. Murphy sold 5,783 shares of the company's stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the sale, the executive vice president now directly owns 48,306 shares of the company's stock, valued at approximately $46,203,239.82. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now directly owns 48,306 shares of the company's stock, valued at approximately $46,203,239.82. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Friday, March 1st. The shares were sold at an average price of $982.05, for a total transaction of $98,205.00. Following the completion of the sale, the director now directly owns 18,282 shares of the company's stock, valued at $17,953,838.10. The disclosure for this sale can be found here. In the last three months, insiders sold 8,095 shares of company stock valued at $7,779,766. Company insiders own 8.83% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. TD Cowen lifted their target price on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a "buy" rating in a research report on Wednesday, April 24th. Morgan Stanley boosted their price objective on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an "overweight" rating in a research report on Wednesday, March 13th. Barclays boosted their price objective on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an "overweight" rating in a research report on Tuesday, January 23rd. Truist Financial reaffirmed a "buy" rating and set a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have assigned a buy rating to the company's stock. According to MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $981.71.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.